A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

Clinical trial NCT03537014 · COMPLETED

Trial details

NCT number: NCT03537014
Sponsor: Resilient Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Posttraumatic Stress Disorder

Start date: 2018-11-21
Primary completion: 2020-08-11
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.